This is a profile image of Matt Craven

Matt Craven

PartnerBay Area

Mobilizes epidemic preparedness and response programs around the world; supports control and elimination of infectious diseases; currently a leader of McKinsey’s public health response to COVID-19

Matt is a leader of McKinsey’s work in infectious diseases and public health within our Social, Healthcare and Public Sector Practice. A physician by training, he has more than 18 years of experience in public health, including five years spent leading infectious disease programs in sub-Saharan Africa. Matt is currently a leader of McKinsey’s public health response to COVID-19.

Matt serves clients across the social, public and private sectors on a range of topics relevant to infectious diseases and public health. He is passionate about the control and elimination of infectious diseases and has worked extensively on HIV, TB, malaria, neglected tropical diseases and vaccine preventable diseases.

Matt is currently a leader of McKinsey’s Public Health response to COVID-19. He has advised on more than 150 organizations on their response to the pandemic, serving clients across sectors and around the world.

Matt has supported major outbreak preparedness programs in Africa, Latin America, and the Caribbean and has worked on a number of outbreak responses. During the 2014-2015 Ebola epidemic, Matt took a leave of absence from McKinsey to serve as Districts Coordinator for the WHO Ebola response team in Sierra Leone. He has worked across five continents and with many of the leading global institutions in public health.

Published work

Future-proofing health systems for climate risks and pandemics,” McKinsey & Company, December 2023

One billion days lost: How COVID-19 is hurting the US workforce,” McKinsey & Company, January 2023

Measuring preparedness: Are public health systems ready for the next pandemic?,” McKinsey & Company, October 2022

When will the COVID-19 pandemic end?,” McKinsey & Company, July 2022

When will the COVID-19 pandemic end?,” McKinsey & Company, March 2022

When will the COVID-19 pandemic end?,” McKinsey & Company, December 2021

Pandemic to endemic: How the world can learn to live with COVID-19,” McKinsey & Company, October 2021

COVID-19: A comparison with other public-health burdens,” McKinsey & Company, September 2021

When will the COVID-19 pandemic end?,” McKinsey & Company, August 2021

The future of Emergency Operation Centers: Six shifts to consider from COVID-19,” McKinsey & Company, July 2021

Genomic sequencing: A vital tool in combatting the pandemic,” McKinsey & Company, April 2021

When will the COVID-19 pandemic end?,” McKinsey & Company, March 2021

COVID-19: Implications for business,” McKinsey & Company, January 2021

When will the COVID-19 pandemic end?,” McKinsey & Company, January 2021

Not the last pandemic: Investing now to reimagine public-health systems,” McKinsey & Company, July 2020

The long haul: How leaders can shift mindsets and behaviors to reopen safely,” McKinsey & Company, July 2020

Contact tracing for COVID-19: New considerations for its practical application,” McKinsey & Company, May 2020

How to restart national economies during the coronavirus crisis,” McKinsey & Company, April 2020

Critical care capacity: The number to watch during the battle of COVID-19,” McKinsey & Company, March 2020

Past experience

Brigham and Women's Hospital
Resident Physician, Internal Medicine and Global Health

Partners In Health (Rwanda)
Physician and Project Manager

SIC Tanzania
Founder and Managing Director

Education

Stanford University School of Medicine
M.D. Medicine

Stanford University
A.B. Economics